AOD-9604 in Enéas Marques — Fat Loss Peptide Research Guide
AOD-9604 research guide for Enéas Marques. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Enéas Marques — Research & Sourcing Guide
For anyone in Enéas Marques looking to source AOD-9604, the foundational reality is that this compound is available only through an online research supply market. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. Vendors worth sourcing from openly share batch-matched Certificates of Analysis documenting HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Enéas Marques researchers need to know about sourcing, verifying, and handling AOD-9604 for research purposes.
What Studies Say About AOD-9604
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Enéas Marques researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade AOD-9604
The most effective path to quality AOD-9604 is community research first — peptide forums track vendor quality over time that are more reliable than search results. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone cannot verify molecular identity. For Enéas Marques researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before committing to research quantities is the accepted approach among experienced researchers. The lyophilised (freeze-dried) form of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Enéas Marques
COA-verified · International tracking · Research grade
AOD-9604 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on preclinical evidence rather than regulated clinical data. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in AOD-9604 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. PubMed represent the most comprehensive research databases for AOD-9604 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
